AstraZeneca's experimental drug sone-ve helped patients with advanced stomach cancer ‌who had received at least two prior treatments to live longer than analysts had expected, according to late-stage trial data presented on Sunday.

Log in or sign up to comment.

No comments yet.

← Back to stories

Create FREE account

or login to continue

Signup with GoogleSignup with GitHubSignup with BlueskySignup with Blacksky
Sign up with email

Already have an account? Log in